Cynata Therapeutics Limited (ASX:CYP)

Market Cap	42.93M
Revenue (ttm)	1.74M
Net Income (ttm)	-8.85M
Shares Out	225.95M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,709
Average Volume	134,651
Open	0.1950
Previous Close	0.1900
Day's Range	0.1900 - 0.1950
52-Week Range	0.1400 - 0.3450
Beta	0.82
RSI	47.33
Earnings Date	May 28, 2025

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYP

Financial Performance

In 2024, Cynata Therapeutics's revenue was 2.32 million, an increase of 39.98% compared to the previous year's 1.65 million. Losses were -9.74 million, -31.75% less than in 2023.